|
[posting]58581131[/posting]Siehe Beitrag aus einem anderen Forum: ... In consideration for the license grant, Wanbang agrees to make upfront, milestone and royalty payments as below: i. US$200,000 upon the signing of this agreement (paid in F2014 and recorded as revenue); ii. US$300,000 upon successful completion of the first line test (paid in F2016 and recorded as revenue); iii. US$500,000 upon successful filing of IND application under CFDA (paid during the period and recorded as revenue); iv. US$500,000 upon receipt of CTA by CFDA for a Phase I study in the territory; v. US$1,500,000 upon receipt of CTA by CFDA for a Phase III study; vi. US$2,500,000 upon successful completion of a first Phase III study; vii. US$4,000,000 upon NDA approval by CFDA in the territory; and viii. Running royalties of 5% on product net sales during the royalty period Read more at http://www.stockhouse.com/companies/bullboard#pbk0boAWPbX2kE… |
|
| aus der Diskussion: | Sirona Biochem |
| Autor (Datum des Eintrages): | Trenibrother (31.08.18 14:06:25) |
| Beitrag: | 7,262 von 31,047 (ID:58583015) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |